ACET
Adicet Bio, Inc. · Healthcare
Insiders bought $1.6M of Adicet Bio, Inc. in the last 12 months
1 insider bought on 1 day.
ACET over the last year
Largest buyers, last 12 months
ACET after insider buys
3 months after each buy, from the first price a copier could get.
4 buys since 2023 with 3 months of prices.
Every filing
92 insider filings since 2016, newest first
Terry Kippley · SVP
Nicolas I Shackley · SVP
Terry Kippley · SVP
Frank Debenedittis · SVP
Satish Srinivasan · Pres, COO - Rising Pharm
Albert L Eilender · Chair
Steven Rogers · SVP and General Counsel
William N Britton · Director
Hans C Noetzli · Director
Charles John Alaimo · SVP
Raymond Bartone · SVP
Terry Kippley · SVP
Nicolas I Shackley · SVP
Satish Srinivasan · Pres, COO - Rising Pharm
Albert L Eilender · Chair
Steven Rogers · SVP and General Counsel
Frank Debenedittis · SVP
Douglas A Roth · SVP and CFO
Salvatore J Guccione Sr · CEO
Albert L Eilender · Chair
Salvatore J Guccione Sr · CEO
Douglas A Roth · SVP and CFO
Steven Rogers · S.VP, GC
Satish Srinivasan · Pres, COO - Rising Pharm
Charles John Alaimo · SVP
Raymond Bartone · SVP
Terry Kippley · SVP
Nicolas I Shackley · SVP
Frank Debenedittis · SVP
Terry Kippley · SVP
William N Britton · Director
Frank Debenedittis · SVP
Satish Srinivasan · Pres, COO - Rising Pharm
Albert L Eilender · Chair
Douglas A Roth · SVP and CFO
Raymond Bartone · SVP
Hans C Noetzli · Director
Frank Debenedittis · SVP
Steven Rogers · S.VP, GC
Charles John Alaimo · SVP
Douglas A Roth · SVP and CFO
Albert L Eilender · Chair
About Adicet Bio, Inc.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.